Abstract:OBJECTIVE: Ulinastatin (UTI) and thymosin alpha 1 (T alpha 1) have been investigated for their immunoregulatory properties in patients with severe sepsis. However, it is unclear whether immunomodulatory therapy using UTI combined with T alpha 1 (UCT), UTI alone (UA), or T alpha 1 alone (TA) improves the disease outcome. The objective of this study was to analyze the effectiveness of UCT, UA, and TA for the treatment of severe sepsis.METHODS: PubMed, EMBASE, and Cochrane Library databases were investigated from inception to September 2015. Randomized controlled trials (RCTs) examining the treatment of patients with severe sepsis by UCT, UA, and TA were defined as eligible. Data were analyzed using Review Manager 5.3, and the RCTs were evaluated by the Cochrane Handbook 5.1.0. The quality of the evidence was evaluated according to the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE).RESULTS: Ten articles and 12 studies were included in this systematic review and meta-analysis. The primary outcome measures indicated that UCT was associated with significantly lower 28-day mortality (risk ratio [RR], 0.67; 95% confidence interval [CI], 0.57-0.80; p < 0.00001; n = 915; GRADE rating, moderate) and 90-day mortality (RR, 0.75; 95% CI, 0.61-0.93; p = 0.009; n = 547; GRADE rating, moderate); UA was associated with no significant difference in the 28-day mortality (RR, 0.60; 95% CI, 0.30-1.20; p = 0.15; n = 182; GRADE rating, low), and there was no report on 90-day mortality; TA was associated with significantly lower 28-day mortality (RR, 0.72; 95% CI, 0.55-0.93; p = 0.01; n = 494; GRADE rating, low), but there was no significant difference in the 90-day mortality (RR, 0.84; 95% CI, 0.54-1.31;p = 0.45; n = 91; GRADE rating, very low). In the secondary outcome measures, there was obvious heterogeneity in the length of the intensive care unit stay and that of the mechanical ventilation, length of the antibiotics and vasopressor use, and 28-day Acute Physiology and Chronic Health Evaluation II (APACHE II) scores.CONCLUSION: Treatment of severe sepsis with UCT reduced both the 28-day and the 90-day mortality, whereas treatment with TA reduced only the 28-day mortality. The effects of UCT, UA, and TA on intensive care unit stay, mechanical ventilation, antibiotics and vasopressor use, and 28-day APACHE II scores of septic patients are still unclear. Additional high-quality RCTs are needed to define clearly the guidelines for the treatment of severe sepsis. (Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.)

Safety of Different Doses of Ulinastatin Combined with Remifentanil in the Treatment of Severe Sepsis in ICU and Their effect on Survival Rate and Organ Function of Patients

A retrospective study of the effectiveness of ulinastatin in the treatment of sepsis

A Retrospective Study of Ulinastatin for the Treatment of Severe Sepsis

Application of a combination of lactated Ringer's solution and ulinastatin for early resuscitation in sepsis

Thymosin Alpha(1)- and Ulinastatin-Based Immunomodulatory Strategy for Sepsis Arising from Intra-Abdominal Infection Due to Carbapenem-Resistant Bacteria

Efficacy of Ulinastatin Combined with Continuous Renal Replacement Therapy in the Treatment of Sepsis Acute Kidney Injury and Its Effects on Systemic Inflammation, Immune Function and miRAN Expression

Clinical efficacy and safety of norepinephrine combined with ulinastatin in the treatment of septic shock

The study of Ulinastatin's curative effect for the patient with sepsis after hepatobiliary surgery

Treatment of patients with severe sepsis using Ulinastatin and Thymosin α1: A prospective, randomized, controlled pilot study

Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Clinical study of ulinastatin on lung injury in patients with septic shock

The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosinα1 for Sepsis: A Systematic Review and Meta-Analysis

Ulinastatin and thymosin α1 combined therapy or monotherapy for severe sepsis：a meta -analysis

Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients

The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis

Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis

[The effect of ulinastatin on disbalance of inflammation and immune status in patients with severe sepsis].

Ulinastatin shortens the length of ICU stay in critical patients with organ failure: A 7-year real-world study

The effect of Ulinastatin on the delivery of cytokines in patients with septic shock

Ulinastatin And/Or Thymosin Alpha 1 for Severe Sepsis: A Systematic Review and Meta-Analysis

Effects of Ulinastatin Plus Xuebijing Injection on Inflammatory Factors in Patients with Sepsis